Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cardiovascular Drugs and Therapy

• Publication date

  2008-02-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10557-008-6092-0PMID 18288595
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral Antidiabetic Agents

  2012cited by this paper
• Inflammation in Atherosclerosis

  2012cited by this paper
• Thiazolidinediones, deadly sins, surrogates, and elephants.

  2007cited by this paper
• A pharmacist-based toxicology service. 1978.

  2007cited by this paper
• Review: 50 years later: is metformin a vascular drug with antidiabetic properties?

  2007influential reference
• Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

  2007cited by this paper
• Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients.

  2007cited by this paper
• Coronary heart disease outcomes in patients receiving antidiabetic agents

  2007cited by this paper
• The Safety of Metformin in Heart Failure

  2007cited by this paper
• Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus

  2007cited by this paper
• Response to comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulphonylureas and metformin. Diabetologia 49:930–936

  2007cited by this paper
• Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

  2006cited by this paper
• Metformin Improves Endothelial Vascular Reactivity in First-Degree Relatives of Type 2 Diabetic Patients With Metabolic Syndrome and Normal Glucose Tolerance

  2006cited by this paper
• Metformin Inhibits Cytokine-Induced Nuclear Factor &kgr;B Activation Via AMP-Activated Protein Kinase Activation in Vascular Endothelial Cells

  2006cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy

  2006cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Metformin does not prevent DNA damage in lymphocytes despite its antioxidant properties against cumene hydroperoxide-induced oxidative stress.

  2006cited by this paper
• Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione

  2006cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2006cited by this paper
• Advanced glycation end products: sparking the development of diabetic vascular injury.

  2006cited by this paper
• Metformin reduces angiotensin-mediated intracellular production of reactive oxygen species in endothelial cells through the inhibition of protein kinase C.

  2006cited by this paper
• Metformin reduces C–reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus

  2005cited by this paper
• Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

  2005cited by this paper
• Contraindications can damage your health—is metformin a case in point?

  2005cited by this paper
• Metformin monotherapy for type 2 diabetes mellitus.

  2005cited by this paper
• Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin.

  2005cited by this paper
• Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells.

  2005cited by this paper
• Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

  2005cited by this paper
• Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study

  2005influential reference
• Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression.

  2005cited by this paper
• Endothelial inflammation in insulin resistance.

  2005cited by this paper
• Metformin and heart failure: innocent until proven guilty.

  2005cited by this paper
• Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study.

  2005cited by this paper
• The incidence of congestive heart failure associated with antidiabetic therapies

  2005cited by this paper
• Metformin improves endothelial function in patients with metabolic syndrome

  2005cited by this paper
• Metabolic syndrome.

  2005cited by this paper
• Effects of short‐term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo‐controlled trial

  2005cited by this paper
• Metformin attenuates progression of carotid arterial wall thickness in patients with type 2 diabetes.

  2004cited by this paper
• Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes

  2004cited by this paper
• Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes.

  2004cited by this paper
• Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.

  2004cited by this paper
• The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial.

  2004cited by this paper
• Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention.

  2004cited by this paper
• Antiatherogenic properties of metformin: the experimental evidence.

  2003cited by this paper
• Oxidative stress as a therapeutic target in diabetes: revisiting the controversy.

  2003cited by this paper
• Do effects on blood pressure contribute to improved clinical outcomes with metformin?

  2003cited by this paper
• The metabolic syndrome.

  2003cited by this paper
• Contraindications to the use of metformin

  2003cited by this paper
• Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.

  2003cited by this paper
• Metformin, but not Thiazolidinediones, Inhibits Plasminogen Activator Inhibitor-1 Production in Human Adipose Tissue in Vitro

  2003cited by this paper
• Pathophysiological implications of insulin resistance on vascular endothelial function

  2003cited by this paper
• Microcirculation in insulin resistance and diabetes: more than just a complication.

  2003cited by this paper
• Beneficial effects of metformin on haemostasis and vascular function in man.

  2003cited by this paper
• Minireview: adiposity, inflammation, and atherogenesis.

  2003cited by this paper
• Molecular motors

  2003influential reference
• Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome

  2003cited by this paper
• Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

  2002cited by this paper
• The effect of dimethylbiguanide on thrombin activity, FXIII activation, fibrin polymerization, and fibrin clot formation.

  2002cited by this paper
• Metformin decreases platelet superoxide anion production in diabetic patients

  2002cited by this paper
• Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

  2002cited by this paper
• Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes.

  2002cited by this paper
• The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.

  2002cited by this paper
• Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.

  2002cited by this paper
• Inflammation in atherosclerosis

  2002cited by this paper
• Improved endothelial function with metformin in type 2 diabetes mellitus.

  2001cited by this paper
• Role of AMP-activated protein kinase in mechanism of metformin action.

  2001cited by this paper
• Metformin: intrinsic vasculoprotective properties.

  2000influential reference
• Effect of four‐week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes

  2000cited by this paper
• Metformin reduces systemic methylglyoxal levels in type 2 diabetes.

  1999cited by this paper
• Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin

  1999cited by this paper
• A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus

  1999cited by this paper
• The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.

  1999cited by this paper
• Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes.

  1999cited by this paper
• FVIII Coagulant Activity and Antigen in Subjects with Ischaemic Heart Disease

  1998cited by this paper
• Effects of Metformin on Collagen Glycation and Diastolic Dysfunction in Diabetic Myocardium

  1998cited by this paper
• Metformin Reduces Circulating Factor VII Concentrations in Patients with Type 2 Diabetes mellitus

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Structure and function of TSPY, the Y-chromosome gene coding for the “testis-specific protein”

  1998cited by this paper
• Metformin: A review of its metabolic effects

  1998influential reference
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Adherence of Mononuclear Cells to Endothelium In Vitro Is Increased in Patients With NIDDM

  1997cited by this paper
• Impaired Peripheral Vasomotion in Diabetes

  1996cited by this paper
• The Effects of High- and Medium-Dose Metformin Therapy on Cardiovascular Risk Factors in Patients With Type II Diabetes

  1996cited by this paper
• Metformin Improves Hemodynamic and Rheological Responses to L-Arginine in NIDDM Patients

  1996cited by this paper
• Microvascular Function in Human Diabetes: A Physiological Perspective

  1995cited by this paper
• Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes

  1995cited by this paper
• The Effects of Metformin on the Capillary Permeability to Albumin in Women Patients with Cyclic Edema

  1995cited by this paper
• Effects of Metformin on Insulin Resistance, Risk Factors for Cardiovascular Disease, and Plasminogen Activator Inhibitor in NIDDM Subjects: A study of two ethnic groups

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Biguanides and NIDDM

  1992influential reference
• Metformin Causes a Reduction in Basal and Post‐venous Occlusion Plasminogen Activator Inhibitor‐1 in Type 2 Diabetic Patients

  1991cited by this paper
• Metformin Decreases the High Plasminogen Activator Inhibition Capacity, Plasma Insulin and Triglyceride Levels in Non-Diabetic Obese Subjects

  1987cited by this paper
• Platelet and endothelial function tests during metformin treatment in diabetes mellitus (short communication).

  1985cited by this paper
• Platelet and endothelial function tests during metformin treatment in diabetes mellitus (short communication).

  1985cited by this paper
• Metformin Improves Peripheral Vascular Flow in Nonhyperlipidemic Patients with Arterial Disease

  1984cited by this paper
• Metformin action on lipid metabolism in lesions of experimental aortic atherosclerosis of rabbits.

  1983cited by this paper
• Release of Cyclic AMP from Chicken Erythrocytes

  1980cited by this paper
• Effect of metformin on lipid metabolism in the rabbit aortic wall.

  1978cited by this paper
• Diabetes and atherosclerosis.

  1971cited by this paper
• Effect of biguanides and atromid on fibrinolysis.

  1967cited by this paper

• Dapagliflozin prevents methylglyoxal-induced retinal cell death in ARPE-19 cells.

  2026cites this paper
• Associations of metformin and sulfonylurea on vascular complications in early- and late-onset type 2 diabetes: A cohort study.

  2026cites this paper
• Effects of the Aqueous Extract of Zingiber officinale Rhizomes and a Combination of Vernonia amygdalina and Ocimum gratissimum leaves on the Fasting Blood Glucose and Lipid Profile Levels of Alloxan-Induced Diabetic Rats

  2025cites this paper
• Metformin suppresses atherosclerosis by dampening extramedullary myelopoiesis.

  2025cites this paper
• Recent Developments in Diabetes Management: Exploring Receptors, Pathways, and Compounds

  2025cites this paper
• Integrated assessment of phytochemicals, Antilipase, hemoglobin antiglycation, antihyperglycemic, antifungal and antibacterial properties of vetiveria zizanioides (L.) Nash

  2024cites this paper
• Antidiabetic potential of Lavandula stoechas aqueous extract: insights into pancreatic lipase inhibition, antioxidant activity, antiglycation at multiple stages and anti-inflammatory effects

  2024cites this paper
• Phytochemical Study and Evaluation of the Antidiabetic and Antihyperglycemic Activities of the Fruit Extracts of Physalis peruviana L. (Solanaceae).

  2024cites this paper
• Heterogeneous response of estimated insulin sensitivity indices to metformin in young individuals with type 1 diabetes and different phenotypes

  2024cites this paper
• Repurposing Metformin for the Treatment of Atrial Fibrillation: Current Insights

  2024cites this paper
• The heterogeneity and effect of diabetes and hypertension on spectral characteristics of vasomotion

  2023cites this paper
• Macrophage immunometabolism in diabetes-associated atherosclerosis

  2023cites this paper
• Antihyperglycemic potential of the Lavandula stoechas aqueous extract via inhibition of digestive enzymes and reduction of intestinal glucose absorption

  2023cites this paper
• Hospital treatment costs associated with incident complications in patients with type 2 diabetes—real-world study based on electronic patient information systems

  2022cites this paper
• The effect of different concentrations of metformin drug on the concentration of glucose and lipid profile in the male rats induced diabetes by alloxan.

  2022cites this paper
• Kakonein restores hyperglycemia‐induced macrophage digestion dysfunction through regulation of cathepsin B‐dependent NLRP3 inflammasome activation

  2022cites this paper
• Effect of Metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: A randomized controlled trial.

  2022cites this paper
• Validated Stability-Indicating Assay UHPLC Method for Simultaneous Analysis of Saxagliptin and Metformin in Fixed-Dose Combinations

  2021cites this paper
• Standardization of Eucalyptus globulus leaves and Cetraria islandica slan

  2021cites this paper
• Potential exploitation of Shea press cakes in glycaemia regulation: Inhibition of α-amylase and α-glucosidase by protein and methanolic extracts

  2021cites this paper
• Characterization of an Endemic Plant Origanum grosii from Morocco: Trace Element Concentration and Antihyperglycemic Activities

  2021cites this paper
• Kakonein restores diabetes‐induced endothelial junction dysfunction via promoting autophagy‐mediated NLRP3 inflammasome degradation

  2021cites this paper
• Regulation of Vascular Function and Inflammation via Cross Talk of Reactive Oxygen and Nitrogen Species from Mitochondria or NADPH Oxidase—Implications for Diabetes Progression

  2020cites this paper
• The Glycocalyx and Its Role in Vascular Physiology and Vascular Related Diseases

  2020cites this paper
• A Study on the Effect of Glucagon Like Peptide 1 Agonist on Glycemic State, Renal Functions and Some Hemodynamic Parameters in Diabetic Male Albino Rats

  2020cites this paper
• Changing Fields-Diabetes Medications Invading the Cardiovascular Space.

  2020cites this paper
• Visceral Obesity and Its Shared Role in Cancer and Cardiovascular Disease: A Scoping Review of the Pathophysiology and Pharmacological Treatments

  2020cites this paper
• Role of the Nox4/AMPK/mTOR signaling axe in adipose inflammation-induced kidney injury.

  2020cites this paper
• Effect of metformin on blood lipids in patients with diabetes mellitus

  2020cites this paper
• Safety evaluation and antihyperglycaemic effect of root extract of Maerua decumbens (Brongn.) DeWolf in Wistar rats

  2020cites this paper
• Deep vein thrombosis: a less noticed complication in hematologic malignancies and immunologic disorders

  2019cites this paper
• Metformin Modulates the Mechanisms of Ageing

  2019cites this paper
• The future of new drugs for diabetes management.

  2019cites this paper
• Insulin resistance: Impact on therapeutic developments in diabetes

  2019cites this paper
• Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials

  2018cites this paper
• Minireview of Adverse Effects of Some Drugs Used in Diabetes Mellitus

  2018cites this paper
• YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus

  2018cites this paper
• Nephroprotective Effects of Metformin in Diabetic Nephropathy

  2017cites this paper
• Metformin: historical overview

  2017cites this paper
• Hyperglycemia-induced oxidative stress and heart disease-cardioprotective effects of rooibos flavonoids and phenylpyruvic acid-2-O-β-D-glucoside

  2017cites this paper
• The use of metformin in patients with chronic kidney disease

  2017cites this paper
• Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway

  2017cites this paper
• Metformin: new insights into an archetypal cardiometabolic drug.

  2017cites this paper
• Metformina: más allá del control glucémico

  2017cites this paper
• Metformin use in renal disease.

  2017cites this paper
• Association between adjunctive metformin therapy in young type 1 diabetes patients with excess body fat and reduction of carotid intima-media thickness.

  2016cites this paper
• Effects of metformin on middle cerebral artery flow velocity in newly diagnosed type 2 Diabetic patients

  2016cites this paper
• Glucose-lowering therapy in type 2 diabetes

  2016cites this paper
• Metformin attenuates expression of endothelial cell adhesion molecules and formation of atherosclerotic plaques via autophagy induction

  2016cites this paper
• Oral Glucose‐Lowering Agents

  2016cites this paper
• Usage of metformin in patients with type 2 diabetes mellitus

  2016cites this paper
• Combined therapy with metformin and insulin attenuates systemic and hepatic alterations in a model of high‐fat diet‐/streptozotocin‐induced diabetes

  2016cites this paper
• METFORMIN EFFECT ON CHEST TUBE DRAINAGE AFTER CORONARY ARTERY BYPASS GRAFT SURGERY

  2015cites this paper
• Tissue Factor Expression in Obese Type 2 Diabetic Subjects and Its Regulation by Antidiabetic Agents

  2015cites this paper
• Regulation of Hyaluronan Synthesis in Vascular Diseases and Diabetes

  2015cites this paper
• Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions

  2015cites this paper
• The effect of prolonged metformin treatment on the activity of the adenylyl cyclase system and NO-synthase in the brain and myocardium of obese rats

  2015cites this paper
• MESA 1: NUEVOS MEDICAMENTOS EN DIABETES MELLITUS TIPO 1

  2015cites this paper
• Augmented AMPK activity inhibits cell migration by phosphorylating the novel substrate Pdlim5

  2015cites this paper
• Is Vitamin D Deficiency Related to Accumulation of Advanced Glycation End Products, Markers of Inflammation, and Oxidative Stress in Diabetic Subjects?

  2015cites this paper
• Intracluster correlation coefficients for sample size calculations related to cardiovascular disease prevention and management in primary care practices

  2015cites this paper
• The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future

  2015cites this paper
• Population Pharmacokinetics of Metformin in Mexican Patients with Type 2 Diabetes Mellitus

  2015cites this paper
• Obesity, insulin resistance, and type 1 diabetes mellitus

  2015influential citation
• The effects of DPP-4 inhibitors on vascular endothelial function in diabetes

  2015cites this paper
• ATOMIC ABSORPTION AND ATOMIC EMISSION SPECTROMETRY FOR THE MICRO-DETERMINATION OF METFORMIN EMPLOYED IN CONTROL OF BLOOD SUGAR LEVEL IN PHARMACEUTICAL FORMULATIONS AND URINE SAMPLES

  2015cites this paper
• Metformin, but Not Rosiglitazone, Attenuates the Increasing Plasma Levels of a New Cardiovascular Marker, Fibulin-1, in Patients With Type 2 Diabetes

  2014cites this paper
• Circulating level of TRAIL concentration is positively associated with endothelial function and increased by diabetic therapy in the newly diagnosed type 2 diabetic patients

  2014influential citation
• Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: relevance to glycemic control.

  2014cites this paper
• Metformin for obesity or overweight

  2014cites this paper
• Improvement of Insulin Reistance in Diet-Induced Obese Mice by Sulodexide, an Endothelial Glycocalyx Mimetic

  2014cites this paper
• Chronic Metformin Treatment is Associated with Reduced Myocardial Infarct Size in Diabetic Patients with ST-segment Elevation Myocardial Infarction

  2014cites this paper
• Exploring the Patient Experience of Changes in Appetite and Diet with Incretin Analogue Therapy

  2014cites this paper
• Vav3, a GEF for RhoA, Plays a Critical Role under High Glucose Conditions

  2014cites this paper
• Role for the endothelial glycocalyx in regulation of insulin sensitivity in muscle

  2014cites this paper
• Metformin in patients with type 2 diabetes and kidney disease: a systematic review.

  2014cites this paper
• Metformin for cardiovascular disease: promise still unproven.

  2014cites this paper
• Regulation of macrophage inflammatory signaling pathways by AMP-activated protein kinase.

  2014cites this paper
• Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia

  2014cites this paper
• Arterial compliance is increased in children with type 2 diabetes compared with normal weight peers but not obese peers

  2013cites this paper
• The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats

  2013cites this paper
• Variables Involved in the Discordance between HbA1c and Fructosamine: The Glycation Gap Revisited

  2013cites this paper
• Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study.

  2013cites this paper
• Effects of two weeks of metformin treatment on whole-body glycocalyx barrier properties in db/db mice

  2013influential citation
• Impact of Diabetes and Peripheral Arterial Occlusive Disease on the Functional Microcirculation at the Plantar Foot

  2013cites this paper
• Effects of telmisartan or amlodipine monotherapy versus telmisartan/amlodipine combination therapy on vascular dysfunction and oxidative stress in diabetic rats

  2013cites this paper
• Potential role of non‐insulin adjunct therapy in Type 1 diabetes

  2013cites this paper
• Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats.

  2013cites this paper
• Tiam-1, a GEF for Rac1, plays a critical role in metformin-mediated glucose uptake in C2C12 cells.

  2013cites this paper
• Serum Homocysteine and Paraoxonase1 Levels in Women with Polycystic Ovary Syndrome Treated with Metformin Versus Metformin and Folic Acid

  2013influential citation
• Efficacy and phytochemical screening of selected plants used in management of diabetes mellitus in Machakos, Kenya

  2013cites this paper
• Pharmacological modulation of insulin resistance : benefits and harms

  2013cites this paper
• Metabolic syndrome and diabetes mellitus in

  2013cites this paper
• A Model In Vitro System to Study Heat Shock Protein 60 (HSP60) Expression in Response to Mitochondrial Impairment in Human Cells

  2013influential citation
• Control blood vessel Diabetic blood vessel Diabetic blood vessel after metformin Circulating blood Solid glycocalyx

  2013influential citation
• Effect of Metformin Glycinate on Glycated Hemoglobin A1c Concentration and Insulin Sensitivity in Drug-Naive Adult Patients with Type 2 Diabetes Mellitus

  2012cites this paper
• Resposta à angiotensina II em artérias mesentéricas de resistência na obesidade: participação das MAPKs.

  2012cites this paper
• Haemostatic Effects of Metformin in Simvastatin‐Treated Volunteers with Impaired Fasting Glucose

  2012cites this paper
• Diabetes: Insulin plus metformin for T2DM—are there benefits?

  2012cites this paper
• Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.

  2012cites this paper